[Angiotensin converting enzyme inhibitors and calcium antagonists: a synergistic action for a better prevention of cardiovascular events].
Treatment of hypertension increasingly requires association of drugs. Among them, the association of calcium antagonists with angiotensin converting enzyme inhibitors is a new tempting approach since the two pharmaceutical classes have synergistic effects on blood pressure lowering and target organ protection whereas their effect is antagonistic for adverse events. Numerous large randomized clinical trials have validated this treatment strategy, and new fixed association are being developed. They apply to hypertensive patients, but also to coronary artery disease patients and more generally speaking to high cardiovascular risk subjects.
Boutouyrie
Pierre
P
Université Paris-Descartes, Faculté de Médecine René Descartes, INSERM, U970, Paris, France. pierre.boutouyrie@egp.aphp.fr
D017311:Amlodipine / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D020913:Perindopril / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004338:Drug Combinations; D017311:Amlodipine; D020913:Perindopril